Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00930423|
Recruitment Status : Unknown
Verified December 2014 by University Hospital, Ghent.
Recruitment status was: Recruiting
First Posted : June 30, 2009
Last Update Posted : December 5, 2014
|Condition or disease|
|Atypical Hemolytic Uraemic Syndrome.|
|Study Type :||Observational|
|Estimated Enrollment :||25 participants|
|Observational Model:||Case Control|
|Official Title:||Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease.|
|Study Start Date :||August 2009|
|Estimated Primary Completion Date :||July 2015|
|Estimated Study Completion Date :||July 2015|
patients with endstage renal failure due to atypical uraemic syndrome treated with hemodialysis.
patiënts with endstage renal failure due to a non complement consuming nephropathy treated with hemodialysis.
- C3a-des-Arg measuring (as a marker of activation). [ Time Frame: at time 0, at 15 minutes, at 60 minutes and at 180 minutes ]
- white blood cell count [ Time Frame: before and after 15 minutes of hemodialysis ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00930423
|Contact: Rogier Caluwé, MDfirstname.lastname@example.org|
|University Hospital Ghent||Recruiting|
|Ghent, Belgium, 9000|
|Contact: Rogier Caluwé, MD email@example.com|
|Principal Investigator: Raymond Vanholder, MD, PhD|
|Sub-Investigator: Rogier Caluwé, MD|
|Principal Investigator:||Raymond Vanholder, MD, PhD||University Hospital, Ghent|